RANBP6

Across TCGA pan-cancer cohorts, RANBP6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RANBP6 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RANBP6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RANBP6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, LSCC, and GBM are the cancer types where RANBP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.888	.003	35	view →
LSCC	OS	Tertile	III,IV	0.522	1.000	.007	18	view →
GBM	DFS	Median	All	0.840	0.651	.004	9	view →
PDAC	DFS	Median	III,IV	0.207	0.487	.001	9	view →
COAD	DFS	Median	All	0.889	1.000	.033	6	view →
HNSC	OS	Quartile	All	0.794	0.956	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RANBP6–LUAD (OS)

Open the LUAD breakdown →